Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”
The first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine kinase inhibitors (TKIs). The choice among the many different immuno-combinations (ICI-ICI or ICI-TKI) is challenging d...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2351669 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850124157608525824 |
|---|---|
| author | Sara Elena Rebuzzi Giuseppe Fornarini Alessio Signori Pasquale Rescigno Giuseppe Luigi Banna Sebastiano Buti |
| author_facet | Sara Elena Rebuzzi Giuseppe Fornarini Alessio Signori Pasquale Rescigno Giuseppe Luigi Banna Sebastiano Buti |
| author_sort | Sara Elena Rebuzzi |
| collection | DOAJ |
| description | The first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine kinase inhibitors (TKIs). The choice among the many different immuno-combinations (ICI-ICI or ICI-TKI) is challenging due to the lack of predictive factors. The different shapes of the Kaplan–Meier survival curves (e.g. “banana-shaped curves”) have raised many questions on the long-term survival benefit. Here, we analyzed the factors that could have impacted the different long-term survival, including the prognostic factors distribution (IMDC score), histological factors (sarcomatoid features, PD-L1 expression), and treatment characteristics (mechanism of action, duration, discontinuation rate). This overview highlights the factors that should be considered in the first-line setting for the patients’ therapeutic choice and prognostic assessment. They are also fundamental parameters to examined for head-to-head studies and real-life, large-scale studies. |
| format | Article |
| id | doaj-art-007c19babd234f0483fcabff2587ada6 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-007c19babd234f0483fcabff2587ada62025-08-20T02:34:23ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2351669Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”Sara Elena Rebuzzi0Giuseppe Fornarini1Alessio Signori2Pasquale Rescigno3Giuseppe Luigi Banna4Sebastiano Buti5Medical Oncology Unit, Ospedale San Paolo, Savona, ItalyMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, ItalyDepartment of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, ItalyTranslationsal and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, UKDepartment of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UKMedical Oncology Unit, University Hospital of Parma, Parma, ItalyThe first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine kinase inhibitors (TKIs). The choice among the many different immuno-combinations (ICI-ICI or ICI-TKI) is challenging due to the lack of predictive factors. The different shapes of the Kaplan–Meier survival curves (e.g. “banana-shaped curves”) have raised many questions on the long-term survival benefit. Here, we analyzed the factors that could have impacted the different long-term survival, including the prognostic factors distribution (IMDC score), histological factors (sarcomatoid features, PD-L1 expression), and treatment characteristics (mechanism of action, duration, discontinuation rate). This overview highlights the factors that should be considered in the first-line setting for the patients’ therapeutic choice and prognostic assessment. They are also fundamental parameters to examined for head-to-head studies and real-life, large-scale studies.https://www.tandfonline.com/doi/10.1080/21645515.2024.2351669Renal cell carcinomaimmune checkpoint inhibitorimmuno-combinationimmunotherapysurvival outcomes |
| spellingShingle | Sara Elena Rebuzzi Giuseppe Fornarini Alessio Signori Pasquale Rescigno Giuseppe Luigi Banna Sebastiano Buti Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau” Human Vaccines & Immunotherapeutics Renal cell carcinoma immune checkpoint inhibitor immuno-combination immunotherapy survival outcomes |
| title | Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau” |
| title_full | Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau” |
| title_fullStr | Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau” |
| title_full_unstemmed | Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau” |
| title_short | Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau” |
| title_sort | banana shaped survival curves of metastatic renal cell carcinoma treated with first line immune combinations not just a matter of palateau |
| topic | Renal cell carcinoma immune checkpoint inhibitor immuno-combination immunotherapy survival outcomes |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2351669 |
| work_keys_str_mv | AT saraelenarebuzzi bananashapedsurvivalcurvesofmetastaticrenalcellcarcinomatreatedwithfirstlineimmunecombinationsnotjustamatterofpalateau AT giuseppefornarini bananashapedsurvivalcurvesofmetastaticrenalcellcarcinomatreatedwithfirstlineimmunecombinationsnotjustamatterofpalateau AT alessiosignori bananashapedsurvivalcurvesofmetastaticrenalcellcarcinomatreatedwithfirstlineimmunecombinationsnotjustamatterofpalateau AT pasqualerescigno bananashapedsurvivalcurvesofmetastaticrenalcellcarcinomatreatedwithfirstlineimmunecombinationsnotjustamatterofpalateau AT giuseppeluigibanna bananashapedsurvivalcurvesofmetastaticrenalcellcarcinomatreatedwithfirstlineimmunecombinationsnotjustamatterofpalateau AT sebastianobuti bananashapedsurvivalcurvesofmetastaticrenalcellcarcinomatreatedwithfirstlineimmunecombinationsnotjustamatterofpalateau |